Introduction: From Innovation to Industry Game-ChangerSince the approval of muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) for the prevention of kidney transplant rejection in 1986, therapeutic MAbs have grown to become the dominant product class within the biopharmaceutical market.The rate of approvals and marketing has grown exponentially, and in...